CXCR2 and familial pancreatic carcinoma: Particularly, inhibition of C-X-C Motif Chemokine Receptor 2 (CXCR2), a neutrophil chemokine receptor, was shown to reduce neutrophil recruitment to tumor, increase T cell infiltration into the tumor, and improve the responses to chemotherapy and T cell-based immunotherapy in pancreatic cancer-bearing mice15–21.